You are here

  • Home
  • Online First
  • Prognostic value of KRAS mutations, TP53 mutations and PD-L1 expression among lung adenocarcinomas treated with immunotherapy

Article info

Article menu
Download PDFPDF
Original research
Prognostic value of KRAS mutations, TP53 mutations and PD-L1 expression among lung adenocarcinomas treated with immunotherapy

Authors

  • Ea Maria Tønning Tønnesen Department of Pathology, Aarhus University Hospital, Aarhus, DenmarkDepartment of Pathology, Viborg Regional Hospital, Viborg, Denmark PubMed articlesGoogle scholar articles
  • Magnus Stougaard Department of Pathology, Aarhus University Hospital, Aarhus, DenmarkDepartment of Clinical Medicine, Aarhus University, Aarhus, Denmark PubMed articlesGoogle scholar articles
  • Peter Meldgaard Department of Clinical Medicine, Aarhus University, Aarhus, DenmarkDepartment of Oncology, Aarhus University Hospital, Aarhus, Denmark PubMed articlesGoogle scholar articles
  • Johanne Lade-Keller Department of Pathology, Aarhus University Hospital, Aarhus, DenmarkDepartment of Clinical Medicine, Aarhus University, Aarhus, Denmark PubMed articlesGoogle scholar articles
  1. Correspondence to Dr Ea Maria Tønning Tønnesen, Department of Pathology, Aarhus University Hospital, Aarhus N, Denmark; Ea{at}pressefoto.dk
View Full Text

Citation

Tønnesen EMT, Stougaard M, Meldgaard P, et al
Prognostic value of KRAS mutations, TP53 mutations and PD-L1 expression among lung adenocarcinomas treated with immunotherapy
Journal of Clinical Pathology Published Online First: 21 November 2022. doi: 10.1136/jcp-2022-208574

Publication history

  • Received August 31, 2022
  • Accepted October 25, 2022
  • First published November 21, 2022.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© Author(s) (or their employer(s)) 2022. No commercial re-use. See rights and permissions. Published by BMJ.